Business Context and Reporting Period
This Form 6-K filing covers the month of June 2010 for Prana Biotechnology Limited (ASX:PBT), a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding the issuance of unlisted options without prior disclosure to investors. The document was signed by Geoffrey Kempler, Executive Chairman, on June 8, 2010.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to equity incentives.
- Ordinary Shares Quoted on ASX: 234,045,871
- New Securities Issued: Two classes of unlisted options issued on June 8, 2010.
- Issue Price: $Nil for both classes.
- Purpose: Employee Incentive Scheme and Consulting Agreements.
Material Changes and New Issuance Details
The primary material change is the issuance of 2,124,609 new unlisted options. These securities rank equally with existing quoted securities upon exercise.
| Class/Code | Number Issued | Exercise Price | Expiry Date |
|---|---|---|---|
| New Class | 1,418,756 | AUD $0.15 | March 31, 2014 |
| PBTAB | 705,853 | AUD $0.00 | August 7, 2014 |
The filing also lists existing unlisted options not quoted on ASX, totaling over 27 million options across various classes (e.g., PBTAB, PBTAD, PBTAF, PBTAG, PBTAI, PBTAK, PBTAM, PBTAO, PBTAQ, PBTAW, PBTAZ) with exercise prices ranging from $Nil to AUD $0.50 and expiry dates between June 2010 and September 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It does not disclose specific risks or contingencies beyond the standard regulatory warranties provided to the ASX regarding the legality of the issue and compliance with the Corporations Act. The company intends to apply for quotation of the newly issued options.
Important Facts for Investor Verification
- Verify the total number of outstanding options and their dilution impact on the 234,045,871 ordinary shares.
- Confirm the specific terms of the "Employee Incentive Scheme" and "Consulting Agreements" referenced as the purpose for the $Nil issue price.
- Check the status of the application for quotation of the new option classes (New Class and PBTAB) with the ASX.
- Note that the filing text does not provide any financial performance data (revenue, earnings, or cash flow) for the period.